Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.62 |
| ▸ | BRAF | P15056 | 14/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.56 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | SRC | P12931 | 2/20 | 0.54 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 1/20 | 0.54 |
| ▸ | HCK | P08631 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31524077 | 0.92 | BRAF (0.52) | BTKBRAFTNK2MAP4K2LCK | |
| SCHEMBL14070166 | 0.86 | BTK (0.70) | BTKBRAFTNK2MAP4K2LCK | |
| SCHEMBL31524190 | 0.85 | BRAF (0.49) | BTKBRAFMAPK14KDRABL1 | |
| SCHEMBL31524013 | 0.84 | BMX (0.55) | BTKBRAFMAPK14KDRSRC | |
| SCHEMBL31524168 | 0.84 | BRAF (0.58) | BRAFKDRPOLB | |
| SCHEMBL31524005 | 0.83 | LCK (0.57) | BTKBRAFLCKKDRSRC | |
| SCHEMBL31524130 | 0.83 | BRAF (0.58) | BRAFKDRPOLB | |
| SCHEMBL31524097 | 0.82 | BRAF (0.49) | BTKBRAFMAPK14 | |
| SCHEMBL4697842 | 0.81 | BRAF (0.64) | BRAFKDRPOLB | |
| SCHEMBL3823481 | 0.80 | KDR (0.64) | BTKBRAFLCKMAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152593-A1 | p38 MAPK INHIBITORS AND USES THEREOF | HOPE CITY (US) | 2025-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152593-A1 | p38 MAPK INHIBITORS AND USES THEREOF | MAPK8, MAPK1, MAPK7 | BTK 730/4885BRAF 49/4885TNK2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.